![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Saturday, February 24, 2024 1:52:50 PM
Kite translation:
- “relapsed or refractory” means a realizable revenue that is a % of a % of a %.
- LBCL is a subset of non-Hodgkin lymphoma (NHL), which is already a subset of Lymphomas
- Relapse refers to treating only recurrent NHL, not newly diagnosed
- Refractory means not SOC for LBCL, but only as a 2nd line of treatment when patient is not responsive to initial treatment
- Car-T is known for high toxicity risks
- Newly diagnosed LBCL in USA each year – 18K
- 30-40% LBCL will need a 2nd line of treatment – 5K to 7K
- Calculation (per Bard, Yescarta has maybe 50% of LBCL) - ~3K patients
Compare that to NWBO’s DCVax-L for brain tumors
- Applicable for the entire brain tumor type
- MAA to MHRA is for approval to treat all GBM, malignant gliomas, and AA
- 1st line of treatment
- Efficacy, non-toxic, immune memory
- Competition: minimal because above and tech platform ideal for combination therapies
- Off label for early stage and benign brain: ideal as a prophylactic to prevent progression
- Newly Diagnosed Primary Brain Tumors in the USA in 2023 – 94K
- GBM and malignant is 28% - 26K patients
- Benign is 72% - Off label means a % of 68K patients, but anticipate eventual label expansion and SOC
https://braintumor.org/brain-tumors/about-brain-tumors/brain-tumor-facts/
NWBO is poised to take the entire brain tumor market. I believe the key to investing in a unicorn company is to hold it long term, ignore the noise and remain disciplined. Years from now, the key will have been the time invested, not timing. Even 20X increase from here will be nothing. The real gains will be the step ladder jumps when new revelations of revenue potential for the DCVax technology platform become apparent, year after year.
![Bullish](/static/images/ih2-bull.png)
Recent NWBO News
- Biophma Announces Exclusive In License for Dendritic Cell Technology, Sending Shares Higher • AllPennyStocks.com • 06/17/2024 04:40:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 09:11:16 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 06/03/2024 09:22:55 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/22/2024 08:13:36 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 09:04:57 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2023 08:36:14 PM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM
ECGI Holdings Announces LOI to Acquire Pacific Saddlery to Capitalize on $12.72 Billion Market Potential • ECGI • Jun 13, 2024 9:50 AM
Fifty 1 Labs, Inc. Announces Major Strategic Advancements and Shareholder Updates • CAFI • Jun 13, 2024 8:45 AM